Abstract: Multiple therapeutic options for renal tumors that are now available have put pathologists under increasing pressure to render diagnosis on limited material. Results on biopsies by hematoxylin and eosin (H&E) have historically not been encouraging. Currently, multiple immunohistochemical markers with differential expression in these renal tumors are available. We studied the utility of such markers on needle biopsies that were obtained ex vivo. After nephrectomy, two 18-guage cores were obtained and processed routinely. Expressions of carbonic anhydrase (CA) IX, CD117, a-methylacyl-CoA racemase (AMACR), cytokeratin 7 (CK7), and CD10 were evaluated. Results, with or without immunostaining, were compared with the final nephrectomy diagnosis. We studied 145 tumors, including 119 renal cell carcinomas (83 clear cell, 18 papillary, 14 chromophobe, and 4 type unclassified), 11 oncocytomas, and 15 miscellaneous tumors. Adequate evaluable material was present in 123 (85%) cases. In such biopsies, 81% of cases were correctly classified by H&E alone, with correct diagnosis in 90% of cases in the most common tumor subtypes (clear cell, papillary and chromophobe renal cell carcinoma, and oncocytoma). By adding immunostains, the accuracy was 90% overall and 99% among the 4 most common subtypes. The following extent and patterns of immuneexpression were highly useful in the diagnoses: diffuse, membranous CAIX expression in clear cell renal cell carcinoma, diffuse positivity for AMACR in papillary renal cell carcinoma, distinct peripheral cytoplasmic accentuation for CD117 in chromophobe renal cell carcinoma, widespread and intense positivity for CK7 in chromophobe and papillary renal cell carcinoma, and diffuse membranous reactivity in clear cell and patchy/luminal in papillary renal cell carcinoma for CD10. In conclusion, utilizing immunostains improves classification of renal tumors on needle biopsy, which may be of particular help for pathologists with limited experience. Both extent and patterns must be considered for a definitive diagnosis.
M alignant renal tumors comprise approximately 3% of all human cancers, the majority of which are renal cell carcinomas, and their incidence is steadily increasing across all population groups. In the United States in 2010, it is estimated that 58,240 patients developed renal tumors and 13,040 deaths were attributed to renal cancer. Approximately 70% are incidentally detected at a tumor size of 4 cm or less. 1, 15, 22 In recent years, advances in the knowledge of the molecular characteristics of each of these tumor types have helped improve the current, clinically more relevant, classification system. 5, 52, 57 It has become clear that these tumor subtypes have different biological potentials ranging from highly aggressive to benign. 5, 52 Owing to vast improvements in the imaging modalities of computed tomography, magnetic resonance imaging, and ultrasound, often performed in response to nonspecific abdominal and musculoskeletal complaints or during the diagnosis and follow-up of other malignancies, currently up to 70% of renal masses are discovered incidentally in some centers, mostly with a median tumor size of less than 4 cm. 21, 22 Over the last decade, the approach to the small renal mass has evolved away from radical nephrectomy toward kidney-sparing surgery for the following reasons: (1) successful oncological control using partial nephrectomy for tumors measuring 4 cm or less 21 or even up to 7 cm, 55 (2) benign nature of up to 23% of resected masses despite contemporary preoperative imaging worrisome for renal cancer, 25, 43 and (3) new concerns that radical nephrectomy is associated with iatrogenic worsening or creation of chronic renal disease 14, 40 with subsequent increased renal and cardiovascular morbidity 13 and decreased overall survival.
or comorbidly ill patients, 1, 48 and more recently, radiofrequency ablation and cryoablation are now commonly utilized in clinical practice for the management of small renal tumors. Radical nephrectomy, however, is still often performed for large tumors, tumors with extension into the renal vein and inferior vena cava or with regional lymphadenopathy, and in metastatic disease as a strategy of cytoreduction before systemic therapies. 35, 36 In metastatic or locally advanced renal cell carcinoma, systemic therapies are becoming increasingly available. In addition, preliminary data show that response is related to the tumor subtype. For example, the recently developed tyrosine kinase inhibitors that target the von Hippel Lindau and hypoxia-inducible factor-1a pathways are effective against clear cell renal cell carcinoma but not against papillary renal cell carcinoma. 26, 28, 29, 34 These factors underscore the importance of knowing the tumor type before a definitive intervention is rendered. Although the majority of epithelial renal tumors can be classified based on characteristic histopathologic features, significant morphologic overlap between the tumor subtypes may make the diagnosis difficult in some cases, particularly when only limited material is available for diagnosis. In earlier studies, attempts at classifying renal tumors by needle biopsy alone have been somewhat disappointing.
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With increasing experience, diagnostic accuracy has improved more recently, particularly in predicting malignancy. 7, 8, 16, 20, 40, 44, 46, 53, 55 However, most of these recent studies have originated from large medical centers handling high volumes of kidney biopsies, 40, 44, 55 and similar results might be difficult to reproduce in centers with more limited experience. Furthermore, it seems highly likely that the low diagnostic accuracy reported earlier in the literature was not only a result of relatively limited experience, but also due to the nonavailability of any reliable and easy-to-use ancillary methods in the past. With the availability of some new immunohistochemical (IHC) markers that show significant differential expression patterns in subtypes of renal tumors, it is now possible to use them adjunctly to help arrive at the correct diagnosis on needle biopsy material, even by pathologists with limited experience. The aim of this study was to assess the diagnostic accuracy of ex vivo needle biopsy, first based on hematoxylin and eosin (H&E) stain alone, and then evaluating the utility of ancillary IHC studies in this assessment.
MATERIALS AND METHODS

Selection of Samples
The study was approved by the Memorial SloanKettering Cancer Center institutional review board. After nephrectomy (partial or total), 2 cores were retrieved from the tumors, before sectioning the specimen and guided by palpation of the tumor, by using an 18-guage needle and were immediately fixed in 10% formalin. All tissue core samples were then routinely processed and embedded in paraffin. H&E slides were prepared from all cases. Histopathologic examination of the needle biopsy cores was performed without knowledge of the final diagnosis of the excised tumor. We followed the World Health Organization classification of renal tumors in all cases. 2 
Immunohistochemistry
As clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, and oncocytoma constitute 90% or more of all renal cortical tumors, we analyzed the utility of a limited panel of currently commonly used 5 IHC markers in improving the diagnostic yield among these common subtypes. These IHC markers used were: carbonic anhydrase (CA) IX (clone M75), CD117 (Dako, Carpinteria, California, polyclonal antibody with citric acid pretreatment at pH 6, final dilution 1:800), a-methylacyl-CoA racemase (AMACR) (Zeta, Sierra Madre, CA, monoclonal rabbit antibody, ethylenediaminetetraacetic acid treatment at pH8, final dilution 1:160), cytokeratin 7 (CK7) (Dako, Carpinteria, CA, monoclonal antibody, treatment with enzyme pronase, protease 14, final dilution 1:10K), and CD10 (Novacastra, Newcastle upon Tyne, UK; monoclonal antibody, citric acid pretreatment, final dilution 1:400). The choice of these markers was based mainly on recent literature supporting their differential expression in renal tumors. CAIX identifies a membranous enzyme/protein whose function is to regulate both intracellular and extracellular pH and whose expression is induced by hypoxic conditions. 18, 19 The expression of this marker is more pronounced in clear cell carcinoma compared with other renal tumors. In this tumor type (clear cell carcinoma), the majority of the tumors express this marker in >85% of tumor cells. 4, 12, 50 In renal tumors other than clear cell carcinoma, when present, its expression tends to be focal and around areas of necrosis. 12, 30 For this study, we used clone M75 for CAIX expression; we later reported that this antibody was equivalent to the commercially available antibody clone NB100-417 (Novus Biological, Littleton, CO). 4 CD117 and CK7 have been shown to stain chromophobe renal cell carcinoma in a characteristic cytoplasmic distribution with peripheral accentuation, whereas oncocytoma exhibits diffuse cytoplasmic immunoreactivity for CD117 but generally is negative for CK7. 3, 23, 41, 42 AMACR and CK7 mark papillary renal cell carcinoma, 42, 49 and CD10 preferentially stains clear cell renal cell carcinoma in a diffuse membranous manner. 6, 42 We first examined the H&E slides on which a diagnosis was rendered in each case. After evaluating IHC findings, the diagnoses were reevaluated and a final core biopsy diagnosis was rendered for each case. Finally, these results were compared with the final pathologic diagnosis on corresponding surgical specimens.
RESULTS
The study included 145 consecutive nephrectomy specimens that were accessioned at our department between July 2004 and February 2005, of which 126 (87%) were ultimately classified as 1 of the 4 most common subtypes of renal cortical tumors, clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, and oncocytoma on the resection specimen (Table 1) . Overall, adequate material for interpretation was present in the needle cores in 119 cases (82%). Of these cases with adequate material, on evaluation of H&E-stained slides alone, correct diagnosis was rendered in 99 of 119 (83%) cases overall, and in 93 of 103 (90%) cases, when only the 4 most common subtypes were taken into consideration (Tables 1 and 2 ). The correct diagnosis in the latter improved to 102 of 103 (99%) cases after using IHC markers (Table 2 ). In addition, 3 more cases with very limited material, in which no diagnosis could be rendered on H&E, were also correctly diagnosed with the usage of IHC studies.
The detailed tumor type-specific results on the needle core biopsies were as follows:
Clear Cell (Conventional) Renal Cell Carcinoma: Overall, there were 83 cases with the final pathologic diagnosis of clear cell renal cell carcinoma, and adequate material was available in the biopsies in 66. Sixtyfour of these were correctly diagnosed on H&E. In 3 additional cases that had very scant amount of tumor tissue present in the biopsies, only the diagnosis of carcinoma was rendered on H&E. There were 2 cases with adequate material, which were not diagnosed as clear cell renal cell carcinoma on H&E. These included 1 with predominant papillary architecture and the other with predominant eosinophilic cytoplasm with sheet-like architecture and low-grade nuclei. After IHC studies, all 66 with adequate material and the additional 3 with limited material were confirmed to be clear cell renal cell carcinoma. Thus, IHC studies helped in diagnosing 5 additional cases as clear cell renal cell carcinoma, increasing the correct diagnostic yield from 64 of 69 (93%) to 69 of 69 (100%) in biopsies with adequate or even scant tumor material. Among the other 14 cases with inadequate material in the biopsies, the yield was nondiagnostic due to cystic renal tumors (n = 7), necrotic tissue only (n = 4), or fibrovascular tissue only (n = 3) in the biopsy material. Papillary Renal Cell Carcinoma: Twenty tumors from 18 patients had the final diagnosis of papillary renal cell carcinoma. However, from 1 patient with 3 separate tumors, only 1 tumor yielded diagnostic material. The remaining 2 tumors were too small to sample (1 cm and 0.6 cm). From 18 tumors that were successfully sampled, 17 (94%) were correctly classified on needle core biopsy by H&E examination alone. One case that was incorrectly placed in the clear cell renal cell carcinoma category had only inconspicuous papillary morphology and areas of necrosis in the needle cores. IHC studies supported the diagnosis of papillary renal cell carcinoma on this case, increasing the correct diagnostic yield to 100%. (18) 18 (100) 17 (94) Chromophobe RCC (14) 13 (93) 8 (62) Oncocytoma (11) 6 (55) 4 (67) RCC, unclassified type (4) 4 (100) 0 (0) Angiomyolipoma (4) 3 (75) 2 (67) Urothelial carcinoma of renal pelvis (3) 3 (100) 2 (67) Miscellaneous tumorsw (8) 6 (86) 2 (33) Total (n = 145)
119 (82) 99 (83) *In 3 additional cases, the diagnosis of carcinoma was rendered but the small amount of tumor cells precluded specific tumor typing.
wMiscellaneous tumors are detailed in Table 3 . RCC indicates renal cell carcinoma. (Tables 1 and 3 ). Six of these were correctly diagnosed by H&E, including 2 of 2 cases of metastases from primary colorectal carcinomas and 2 of 3 urothelial carcinomas. In addition, in spite of no definite diagnosis, in all 4 cases with the final diagnosis of renal cell carcinoma unclassified type we were able to successfully assign them to either a low-grade or highgrade tumor category based on nuclear pleomorphism, mitotic activity, and presence of tumor necrosis.
Immunohistochemistry
Of the initial cohort, 113 cases representing the most common 4 subtypes of renal epithelial neoplasms, and renal cell carcinoma unclassified type, were further subjected to IHC studies. These included 74 clear cell (1) 1 (100) 0 Birt-Hogg-Dube´syndrome (1) 1 (100) 0 Wilms tumor (1) 1 (100) 0 Adrenocortical carcinoma (1) 1
renal cell carcinomas, 17 papillary renal cell carcinomas, 13 chromophobe renal cell carcinomas, 5 oncocytomas, and 4 renal cell carcinoma unclassified type. Results on IHC findings are summarized in Table 4 .
All cases of clear cell renal cell carcinoma showed immunoreactivity with CAIX. The expression was diffuse and intense membranous in all but 2 cases. The expression was detected in 100% of the tumor cells in 41 of 69 cases (59%) and in >50% in 58 cases (85%). In only 2 cases, the expression was limited to 10% and 20% of tumor cells, respectively. All cases with eosinophilic cytoplasm showed strong and diffuse CAIX staining in a membranous pattern similar to that displayed by tumors with exclusive clear cytoplasm. In papillary renal cell carcinoma, CAIX was detected in 10 of 14 cases (71%). However, this expression was primarily limited to perinecrotic areas or tips of the papillae. In 8 cases, the expression was limited to less than 20% of tumor cells and in only 2 cases it approached 50%. None of the 5 oncocytoma cases showed immunoreactivity with CAIX, whereas only 1 case of chromophobe renal cell carcinoma showed a small cluster of cells reactive with this antibody in a perinecrotic location. Examples of CAIX expression in different tumor types are illustrated in Figure 1 . All but 1 case of papillary renal cell carcinoma expressed AMACR in an intense, cytoplasmic, finely granular, and diffuse (>75% of tumor cells) pattern. In 1 case, only 40% of tumor cells were immunoreactive. In clear cell renal cell carcinoma, AMACR expression was detected in 46 of 68 cases ranging from 5% to 100% of tumor cells (median 40%). In oncocytoma, AMACR expression was detected in 3 of 5 cases in 5%, 30%, and 60% of tumor cells, respectively. In chromophobe renal cell carcinoma, AMACR expression was detected in 5 of 13 cases, ranging from 5% to 70% of tumor cells (median 30%). Examples of AMACR staining are illustrated in Figure 2 .
CD117 was most frequently expressed in chromophobe renal cell carcinoma, being positive in 8 of 14 cases. In 4 of the positive cases, the expression was present in >80% of tumor cells. In another case, it was expressed in 50% of tumor cells and in the remaining 3 cases it was expressed in 20% (2 cases) and 10% of tumor cells (1 case). Immunoreactivity was diffuse cytoplasmic with peripheral accentuation in 7 cases. In 1 case, staining was exclusively cytoplasmic without peripheral accentuation. In all other subtypes, whenever there was any positivity, the expression was only cytoplasmic and weak in <20% of tumor cells (Fig. 3) . In particular, all 5 oncocytomas showed variable expression of CD117, present in 20% to FIGURE 3 . CD117 expression in intense and diffuse cytoplasmic patterns with peripheral accentuation in chromophobe renal cell carcinoma (A) and only focal and cytoplasmic in oncocytoma (B), but rarely focally discontinuous membranous (inset). CK7 expression in chromophobe renal cell carcinoma in a cytoplasmic pattern with distinct peripheral accentuation (C), whereas in oncocytoma, it was only focal (D).
80% of tumor cells in a weak cytoplasmic pattern. In 2 cases, discontinuous membranous accentuation was also noted.
CK7 expression was widespread and intense in chromophobe renal cell carcinoma (10 of 11 cases, 91%) and papillary renal cell carcinoma (15 of 17 cases, 88%). In both subtypes, the expression predominantly highlighted the cellular outlines (Fig. 3) . Eight of 10 chromophobe renal cell carcinoma cases expressed CK7 in >80% of tumor cells and in the remaining 2 cases it was expressed in 50% and 20% of tumor cells, respectively. In papillary renal cell carcinoma, the expression ranged form 30% to 100% of tumor cells (median 80%). In clear cell renal cell carcinoma, CK7 was expressed in 19 of 74 cases (26%), ranging from 1% to 100% (median 10%) with only 4 cases exhibiting expression in >50% of tumor cells. All clear cell renal cell carcinomas with the latter patterns of staining had predominantly tubular and/or cystic growth patterns or areas with scars. Only 1 of 5 oncocytomas showed rare cells expressing CK7 (<5% of tumor cells).
CD10 was most commonly expressed in clear cell renal cell carcinoma (67 of 74 cases; 91%) and papillary renal cell carcinoma (13 of 17; 76%). In clear cell renal cell carcinoma, the expression ranged from 5% to 100% of tumor cells (median 70%) and was expressed in >50% of tumor cells in 56 of the 67 cases (84%), predominantly in a distinct membranous pattern. In papillary renal cell carcinoma, the expression was variable in extent, ranging from 5% to 100% of tumor cells (median 20%) and was predominantly luminal, along the apical aspect of the papillary fronds, in addition to membranous staining (Fig. 4) . In both oncocytoma and chromophobe renal cell carcinoma, expression was widely variable, ranging from 5% to 70% of tumor cells in a cytoplasmic distribution.
Of the 4 most common subtypes of the tumors, improvement in diagnostic accuracy was seen in all groups, as detailed above (and Table 2 ). The improvement was most evident in the chromophobe renal cell carcinoma/oncocytoma category.
Some examples of cases in which the diagnosis on H&E was not straightforward, and the immunostains helped in the correct classification of the tumor are as follows: (1) One case of clear cell renal cell carcinoma had eosinophilic cytoplasm with perinuclear clearing and low nuclear grade, resembling chromophobe renal cell carcinoma. The expression of CAIX and CD10 was diffuse and membranous and both CK7 and CD117 were negative, allowing this case to be placed in the correct category (Fig. 5) . (2) In 4 tumors with diffuse cytoplasmic eosinophilia and only a minor degree of nuclear pleomorphism, both oncocytoma and chromophobe renal cell carcinoma entered in the differential diagnosis. The presence of crush or processing artifact made the distinction between the 2 entities more difficult. The expression of CK7 and CD117 was diffuse cytoplasmic with distinct peripheral accentuation in all 4 cases, making it possible to assign the tumors to the chromophobe renal cell carcinoma category (Fig. 6) . (3) In some papillary renal cell carcinomas with inconspicuous papillary morphology and focal necrosis, the diagnosis of clear cell renal cell carcinoma could not be ruled out on biopsy material by H&E alone. However, in these cases the tumor cells were strongly and diffusely reactive with AMACR and CK7. In addition, CAIX reactivity was limited to cells immediately adjacent to areas of necrosis, allowing these to be correctly placed in the papillary renal cell carcinoma category. (4) In another example in which the tumor had a predominantly papillary architecture in the biopsy material, its immunoprofile of strong diffuse and membranous CAIX, lack of AMACR staining, and only focal CK7 positivity placed this tumor in the clear cell renal cell carcinoma category, which was confirmed on the final diagnosis on the excised specimen (Fig. 7) .
DISCUSSION
In this study, we explored the ability to classify solid renal masses by needle biopsy that were obtained ex vivo. Using H&E alone, correct diagnosis was made on the biopsies with adequate material in 83% overall and in 90% among the 4 most common types of renal cortical tumors. In the latter group, the diagnostic accuracy was the highest in clear cell renal cell carcinoma, followed closely by papillary renal cell carcinoma. Proportionately fewer cases of oncocytoma and chromophobe renal cell carcinoma were diagnosed correctly on H&E. Usage of the limited panel of 5 IHC markers further increased our overall diagnostic accuracy to 90% and to 99% when only the 4 most common renal cortical tumors were considered. We feel that this finding is important given the fact that 90% of primary renal neoplasms fall into 1 of these categories. Knowing which of these tumor types is present may influence therapy, including the option of surveillance. In cases in which the differential includes other types of tumor, it is logical that the panel can be modified as needed. For example, adding an assay for TFE-3 or TFE-B in cases in which a translocationassociated carcinoma is a consideration or adding HMB-45 and Mart-1 in potential cases of epithelioid angiomyolipoma could be warranted.
A number of earlier studies focusing on the accuracy and the utility of needle biopsy of solid renal tumors have yielded conflicting results. Some conclude that the procedure is frequently inadequate for definitive tissue diagnosis and lacks specificity and sensitivity. 11, 56 Others, similar to our observations, conclude that biopsies can in fact be adequate for rendering a definitive diagnosis in most cases, and can have a significant impact on the management of renal masses. As such, Richter et al 33 demonstrated that up to 76% of renal mass lesions diagnosed as indeterminate by imaging modalities provided a definitive diagnosis in their biopsy specimens. Wood et al 56 reported that in 41% of their patients, biopsy diagnosis altered clinical management. Shah et al 39 found that 79% of their biopsies were adequate for assessment and the diagnosis was accurate in 98% of the 110 biopsies that were analyzed. Beland et al 8 were able to accurately diagnose 90% of the 58 needle biopsies that they performed on solid renal masses. Similar results were achieved by several other investigators, indicating that a highly accurate diagnosis can be achieved when sufficient tissue sample is obtained by needle biopsy. 7, 20, 37, 44, 46 Other investigators have shown that the results of tissue diagnosis by needle biopsy were accurate and were helpful in clinical decision making in patients with small renal mass lesions. For example, some of the patients with a benign diagnosis on the needle biopsy were spared surgical intervention and were managed by observation or ablative procedures. 24, 27, 40, 44, 51, 54 By applying IHC markers, our accuracy rate in identifying the 4 most common renal cortical tumors increased from 90% to 99%. Although the panel of IHC markers we applied is modest (5 markers), it seems sufficient to arrive at the correct diagnosis in a vast majority of cases, including those with questionable diagnosis due to limited material or uncommon cytoarchitectural features on H&E alone. More importantly, all the markers are readily available and are commonly used by many laboratories in the routine work-up of surgical pathology cases.
Clear cell renal cell carcinoma is the most common of the solid renal tumors removed surgically and is the most common of the renal epithelial tumors to develop metastases. 10, 26, 32 It is also the subtype that is currently considered to be most amenable to targeted therapies such as tyrosine kinase inhibitors and inhibitors of mammalian target of rapamycin. 38 Hence, it is particularly important to be able to diagnose this subtype or exclude it in favor of other more indolent or even aggressive nonclear cell tumors. Overall, by H&E only, 77% of all clear cell renal cell carcinomas with attempted biopsies were correctly diagnosed. If only the cases with adequate material for H&E evaluation present in the cores are considered, we were able to render the correct diagnosis of clear cell renal cell carcinoma in 64 of 66 cases (97%). In "difficult to classify" cases, and occasionally "very limited material" situations, the immunoprofile of these tumors was helpful in solving the diagnostic dilemma in many cases. CAIX would be most helpful in cases of clear cell renal cell carcinoma with eosinophilic cytoplasm and low nuclear grade that may superficially resemble a chromophobe renal cell carcinoma, as it is consistently and preferentially expressed in an intense, diffuse membranous pattern in the majority of clear cell renal cell carcinomas. This marker is either negative or its expression is focal and usually limited to areas surrounding necrosis in other tumor types, as has also been reported previously. in a membranous and less commonly cytoplasmic pattern. CD117 and CK7 are expressed in chromophobe renal cell carcinoma in a distinct diffuse cytoplasmic pattern with peripheral accentuation, unlike their variable and focal cytoplasmic expression in clear cell renal cell carcinoma.
Other situations in which IHC studies were helpful in arriving at correct diagnoses were tumors with clear cell histology growing in a predominantly papillary pattern or a papillary renal cell carcinoma displaying an inconspicuous papillary pattern or showing cytoplasmic clearing of the tumor cells. A combination of diffuse membranous immunoreactivity for CAIX and CD10 and lack of labeling with AMACR would favor a clear cell renal cell carcinoma over papillary renal cell carcinoma, especially in the absence of CK7 expression. In contrast, a combination of diffuse granular cytoplasmic expression with AMACR and a diffuse membranous and cytoplasmic expression of CK7 would place a tumor in the papillary renal cell carcinoma category. 6, 49 CD10 may be present in papillary renal cell carcinoma, usually not in a diffuse manner but in a luminal pattern. CAIX may be present usually at the tips of the papillae or around areas of necrosis, 30, 50 which most likely represents areas of ischemia.
One of the most challenging differential diagnoses is between chromophobe renal cell carcinoma and oncocytoma, especially if the former is predominantly eosinophilic. The overlapping nuclear, cytoplasmic, and architectural characteristics between these 2 entities have been well documented in the literature. 3, 31, 47 Indeed, the lowest rate of diagnostic accuracy among the common renal cortical tumor subtypes that we encountered on H&E was in these 2 categories. However, we found that the combination of quantitative and qualitative IHC features of CD117 and CK7 are quite useful in their differentiation. A diffuse cytoplasmic pattern of staining with peripheral accentuation by both markers is characteristic of chromophobe renal cell carcinoma. Oncocytomas are likely to be diffusely immunoreactive for CD117 in a cytoplasmic distribution, whereas CK7 is either negative or focal. Despite the improvement of our diagnostic accuracy using this immunoprofile, the overall number of cases in these 2 categories was relatively small to make a definitive conclusion and more studies with larger cohorts are needed to confirm these observations.
A minority of the lesions that we encountered did not belong to any of the common subtypes of renal cortical neoplasms. Nonetheless, we were able to reach a correct diagnosis in the majority of them. However, we were not able to correctly diagnose the 4 cases of renal cell carcinoma unclassified type on needle biopsy, as this entity requires careful inspection of a thoroughly sampled tumor before making the determination that it does not fit into any of the well-recognized entities. Thus, it is a diagnosis of exclusion. However, additional information can be obtained from such cases by documenting the presence of necrosis or high nuclear grade morphology, which may help to stratify these tumors to different risk groups.
One important factor in our study was that the yield of the ex vivo needle biopsy procedure was satisfactory in 82% of cases. This may not necessarily be the case in vivo in which the specimen is obtained through an imageguidance biopsy (ultrasound or computed tomography). We were not able to retrieve adequate material on a significant number of lesions measuring 1.5 cm or less, or lesions that were predominantly necrotic. It is likely that the yield would be higher under ultrasound guidance, as it would otherwise be performed in the in vivo setting.
The ex vivo nature of this study may be a limitation, as easy access to the tumor can be controlled and it offers an advantage over obtaining similar samples in a clinical setting. We always obtained all our samples from intact nephrectomies before sectioning the specimen and exposing the tumor. The purpose was to make it practically as close as possible to clinical settings, in which image guidance is often used to enhance the yield, and potentially acting similar to sampling ex vivo. However, it is interesting to note that our nondiagnostic rate is similar to that reported in the literature for in vivo biopsies. 17 In contrast, having an ex vivo design of this study allowed us to compare our diagnosis on the needle biopsy with that of the final diagnosis of the resected tumor. This scenario may not always be applicable in all clinical settings, as some needle biopsy procedures may not be necessarily followed by nephrectomy. 56 The validation of our ex vivo findings in a clinical setting is essential and will be pursued in the future.
Nonetheless, our study serves as a proof of principle that, if an adequate biopsy sample is provided to the pathologist, H&E evaluation in combination with judicious use of IHC studies can result in an accurate diagnosis in over 90% of cases. The need to render a diagnosis on solid renal masses is likely to increase as we put a larger premium on customizing therapy to the individual patient. 9, 17, 54 Based on our results, we believe that the usage of this limited IHC panel might be useful even for the pathologists with limited experience in renal biopsies.
In summary, needle biopsy of the kidney is an important and useful tool and its diagnostic utility is enhanced by IHC studies. Despite quantitative variability and overlapping features, the extent and pattern of expression of these IHC markers are strong adjuncts in the classification of the most common renal neoplasms. We believe that our study serves as a proof of principle for the application of IHC assays to the diagnosis of renal tumors on needle biopsy, and suggests its potential utility even for pathologists with limited experience in the interpretation of renal needle core biopsies.
